| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4168 Stock Overview
GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan.
GlycoNex Incorporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$25.85 |
| 52 Week High | NT$34.20 |
| 52 Week Low | NT$23.60 |
| Beta | 1.16 |
| 1 Month Change | -13.83% |
| 3 Month Change | -8.50% |
| 1 Year Change | -11.78% |
| 3 Year Change | 23.98% |
| 5 Year Change | -7.01% |
| Change since IPO | -46.55% |
Recent News & Updates
Here's Why We're Not At All Concerned With GlycoNex Incorporation's (GTSM:4168) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. Indeed, GlycoNex...
Shareholder Returns
| 4168 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -6.8% | -5.1% | -3.4% |
| 1Y | -11.8% | 9.1% | 0.7% |
Return vs Industry: 4168 underperformed the TW Biotechs industry which returned 9.1% over the past year.
Return vs Market: 4168 underperformed the TW Market which returned 0.7% over the past year.
Price Volatility
| 4168 volatility | |
|---|---|
| 4168 Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4168 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 4168's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Mei-Chun Yang | https://www.glyconex.com.tw |
GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. Its technology platform enables glycan-directed cancer therapy and analytical tools for glycosylation. The company develops GNX102, a humanized antibody for cancer; and GNX201, GNX202, GNX203, and GNX204 for various solid tumors.
GlycoNex Incorporation Fundamentals Summary
| 4168 fundamental statistics | |
|---|---|
| Market Cap | NT$2.52b |
| Earnings (TTM) | -NT$172.49m |
| Revenue (TTM) | NT$5.48m |
460.3x
P/S Ratio-14.6x
P/E RatioIs 4168 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4168 income statement (TTM) | |
|---|---|
| Revenue | NT$5.48m |
| Cost of Revenue | NT$2.01m |
| Gross Profit | NT$3.46m |
| Other Expenses | NT$175.95m |
| Earnings | -NT$172.49m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.77 |
| Gross Margin | 63.21% |
| Net Profit Margin | -3,150.56% |
| Debt/Equity Ratio | 0.0% |
How did 4168 perform over the long term?
See historical performance and comparisonValuation
Is GlycoNex Incorporation undervalued compared to its fair value and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
1.85x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4168's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 4168's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 4168 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 4168 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4168's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4168 is good value based on its PB Ratio (1.9x) compared to the TW Biotechs industry average (3.8x).
Future Growth
How is GlycoNex Incorporation forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
125.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlycoNex Incorporation has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has GlycoNex Incorporation performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-3.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4168 is currently unprofitable.
Growing Profit Margin: 4168 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4168 is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare 4168's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4168 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-29%).
Return on Equity
High ROE: 4168 has a negative Return on Equity (-12.69%), as it is currently unprofitable.
Financial Health
How is GlycoNex Incorporation's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 4168's short term assets (NT$358.7M) exceed its short term liabilities (NT$27.2M).
Long Term Liabilities: 4168's short term assets (NT$358.7M) exceed its long term liabilities (NT$8.9M).
Debt to Equity History and Analysis
Debt Level: 4168 is debt free.
Reducing Debt: 4168 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4168 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4168 has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 23% each year.
Dividend
What is GlycoNex Incorporation current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4168's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4168's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4168's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4168's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 4168 is not paying a notable dividend for the TW market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 4168 has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Mei-Chun Yang
no data
Tenure
Dr. Mei-Chun Yang serves as the President and Chief Executive Officer at GlycoNex Incorporation. She served as Director of Glyconex Incorporation.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
GlycoNex Incorporation's employee growth, exchange listings and data sources
Key Information
- Name: GlycoNex Incorporation
- Ticker: 4168
- Exchange: TPEX
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$2.520b
- Shares outstanding: 97.48m
- Website: https://www.glyconex.com.tw
Location
- GlycoNex Incorporation
- No. 97, Xintai 5th Road
- 8th Floor
- New Taipei City
- 221
- Taiwan
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/15 00:00 |
| End of Day Share Price | 2022/05/13 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.